Effectiveness of Benralizumab in Reducing Asthma and COPD Exacerbations in Patients with Severe Asthma and Concomitant COPD: Real-World Evidence from the ZEPHYR-5 Study.

Muhammad Adrish, Jessica K DeMartino, Donna Carstens, Mandy Jackson, Kathleen Wilson, Jill Schinkel, Joseph Tkacz

Abstract read

In one paragraph

Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Benralizumab Reduces Asthma Exacerbations and Costs Among Medicare Beneficiaries with Severe Asthma: The ZEPHYR-5 Study.Journal of asthma and allergy · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Muhammad AdrishBaylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-5553-6182

Jessica K DeMartinoAstraZeneca, Wilmington, DE, USA.

Donna CarstensAstraZeneca, Wilmington, DE, USA.

Mandy JacksonAstraZeneca, Wilmington, DE, USA.

Kathleen WilsonInovalon, Bowie, MD, USA.

Jill SchinkelInovalon, Bowie, MD, USA.

Joseph TkaczInovalon, Bowie, MD, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This real-world evidence study sought to evaluate the effectiveness of benralizumab on reducing both asthma and COPD exacerbations among patients with a diagnosis of asthma and concomitant COPD. Patients and Methods: This study was a non-interventional, single-arm, retrospective database analysis of the MORE Results: A total of 2894 patients with asthma and concomitant COPD were included. Following initiation of benralizumab, the mean (SD) number of total asthma exacerbations decreased by 39.2% (from 4.0 (2.2) to 2.4 (2.4) exacerbations/year; Conclusion: This study provides real-world evidence supporting the effectiveness of benralizumab in reducing both asthma and COPD exacerbations and decreasing reliance on corticosteroids, particularly among those with elevated eosinophil levels.

Indexed as

Anti-Asthmatic AgentsAntibodies, Monoclonal, HumanizedAsthmaLungPulmonary Disease, Chronic ObstructiveAgedAged, 80 and overDatabases, FactualDisease ProgressionEosinophilsFemaleHumansMaleMiddle AgedRegistriesRetrospective StudiesAnti-Asthmatic AgentsAntibodies, Monoclonal, Humanizedbenralizumabasthmabenralizumabbiologicsblood eosinophilsCOPDexacerbations

Identifiers

PMID41859014

DOI10.2147/COPD.S562498

PMCPMC12997770

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.